"Benzenesulfonates" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Organic salts and esters of benzenesulfonic acid.
| Descriptor ID |
D001557
|
| MeSH Number(s) |
D02.455.426.559.389.097 D02.886.645.600.080.050.100
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Benzenesulfonates".
Below are MeSH descriptors whose meaning is more specific than "Benzenesulfonates".
This graph shows the total number of publications written about "Benzenesulfonates" by people in this website by year, and whether "Benzenesulfonates" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2005 | 1 | 3 | 4 |
| 2006 | 4 | 1 | 5 |
| 2007 | 2 | 1 | 3 |
| 2008 | 4 | 0 | 4 |
| 2009 | 6 | 1 | 7 |
| 2010 | 5 | 1 | 6 |
| 2011 | 3 | 2 | 5 |
| 2012 | 1 | 0 | 1 |
| 2024 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Benzenesulfonates" by people in Profiles.
-
The value of calcofluor white in the diagnosis of invasive fungal diseases. Diagn Microbiol Infect Dis. 2024 Apr; 108(4):116186.
-
Phase I study investigating the safety and feasibility of combining imatinib mesylate (Gleevec) with sorafenib in patients with refractory castration-resistant prostate cancer. Br J Cancer. 2012 Aug 07; 107(4):592-7.
-
Resampling phase III data to assess phase II trial designs and endpoints. Clin Cancer Res. 2012 Apr 15; 18(8):2309-15.
-
Sorafenib inhibits neuroblastoma cell proliferation and signaling, blocks angiogenesis, and impairs tumor growth. Pediatr Blood Cancer. 2012 Oct; 59(4):642-7.
-
Sorafenib-induced eruption resembling pityriasis rubra pilaris. J Am Acad Dermatol. 2011 Aug; 65(2):452-453.
-
Novel molecular targeted therapies for refractory thyroid cancer. Head Neck. 2012 May; 34(5):736-45.
-
Baseline patient-reported kidney cancer-specific symptoms as an indicator for median survival in sorafenib-refractory metastatic renal cell carcinoma. J Cancer Surviv. 2011 Sep; 5(3):255-62.
-
Two drug interaction studies of sirolimus in combination with sorafenib or sunitinib in patients with advanced malignancies. Clin Cancer Res. 2011 Apr 01; 17(7):1956-63.
-
A phase II study of sorafenib in malignant mesothelioma: results of Cancer and Leukemia Group B 30307. J Thorac Oncol. 2010 Oct; 5(10):1655-61.
-
Gemcitabine plus sorafenib in patients with advanced pancreatic cancer: a phase II trial of the University of Chicago Phase II Consortium. Invest New Drugs. 2012 Feb; 30(1):382-6.